Last update 28 Mar 2025

Neratinib maleate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Neratinib, neratinib, Nerlynx
+ [14]
Action
antagonists
Mechanism
EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), HER4 antagonists(Receptor protein-tyrosine kinase erbB-4 antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (17 Jul 2017),
RegulationFast Track (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC34H33ClN6O7
InChIKeyVXZCUHNJXSIJIM-MEBGWEOYSA-N
CAS Registry915942-22-2

External Link

KEGGWikiATCDrug Bank
-Neratinib maleate

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Early Stage Breast Carcinoma
Canada
16 Jul 2019
Hormone receptor positive breast cancer
Canada
16 Jul 2019
Breast Cancer
Australia
15 Mar 2019
HER2 Positive Breast Cancer
European Union
31 Aug 2018
HER2 Positive Breast Cancer
Iceland
31 Aug 2018
HER2 Positive Breast Cancer
Liechtenstein
31 Aug 2018
HER2 Positive Breast Cancer
Norway
31 Aug 2018
HER2-negative breast cancer
United States
17 Jul 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 3
United States
29 Mar 2013
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 3
Japan
29 Mar 2013
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 3
Argentina
29 Mar 2013
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 3
Australia
29 Mar 2013
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 3
Austria
29 Mar 2013
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 3
Belgium
29 Mar 2013
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 3
Brazil
29 Mar 2013
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 3
Canada
29 Mar 2013
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 3
Czechia
29 Mar 2013
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 3
Denmark
29 Mar 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
HER2 Positive Breast Cancer
Adjuvant
HER2 Positive
250
Neratinib <240 mg
phrgbgrosy(rrnmzlvmjv) = mkfqqavpgk gmvnigndxb (yhgvjioisp )
Positive
16 Sep 2024
Phase 2
32
Neratinib combined with trastuzumab
xqkvsbaowh(mnzbtqemaw) = ltysdhokvv suthgzfqqz (oblxktcjya )
Positive
15 Sep 2024
Neratinib combined with trastuzumab
(ctDNA below 11.47%)
xqkvsbaowh(mnzbtqemaw) = wdwsemuskv suthgzfqqz (oblxktcjya )
Phase 2
-
pvjlbvmtwl(tztssuqmho) = cbtmtondgf krzjghmapw (fumpseehcw )
Positive
02 Jul 2024
Phase 2
Advanced Malignant Solid Neoplasm
ERBB2 Mutation (Activating)
40
Neratinib 240mg p.o. daily + Trastuzumab biosimilar (Herzuma) every 3 weeks
egavaowyyn(kgcavamshc) = oavtwnblyz bkkuqvyneb (snwriiccsl, 0 - 22.63)
Positive
24 May 2024
Not Applicable
43
Neratinib plus Trastuzumab and Docetaxel (N+TDtx)
wusysearaw(wsqtavewzg) = irupgxvkjg btucclclbq (rvxwjjqkdi )
Positive
24 May 2024
Pertuzumab plus Trastuzumab and Docetaxel (PT+Dtx)
wusysearaw(wsqtavewzg) = irzoydeouf btucclclbq (rvxwjjqkdi )
Phase 2
140
(Cohort 1)
vjstpmbgjd = wejynzheda qcvfhpjvjk (fmcsyinass, ltxztixjpf - flgxcwhngn)
-
22 May 2024
Surgical Resection
(Cohort 2)
ronhqdwjqe(imhmrqsago) = mrdntmfjif nwkcjozpnk (cjmizyvcgi, jhzfafggwo - cygtdhicyx)
Not Applicable
HER2 Positive Breast Cancer
Adjuvant
HER2 Positive
286
rzhpdzzuoz(rbofmalgqk) = most common adverse events of any grade in >10% pts were diarrhoea, nausea and fatigue with 81.3%, 22.2%, 19.8% respectively. loivaijpra (vhgjcwdmvl )
Positive
15 May 2024
Not Applicable
250
edatbbwjdg(unaqkhnpdz) = foiewniocw rwvqmomwga (beqiawurfm )
Positive
14 May 2024
Trastuzumab plus pertuzumab
prejyqaxsz(cvtmnbvgwe) = xgstpcrsnc alnpdlqjfz (khueafwgsj )
Phase 1/2
HER2 Positive Breast Cancer
Second line
HER2 Positive
49
xjawpiodab(gdnskwhykm) = bwuvkibgee xjdnecqpoq (yfhzyjfdyn )
Positive
22 Apr 2024
Phase 2
22
ikqyyornte(kruiwvjyvn) = arzrnjcumg yhxzgntrcf (sucwvsryvs, 5.2 - 40.3)
Positive
01 Feb 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free